Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease
FDA Approval Insights: Ponatinib in Ph+ ALL
Utah Governor’s Medal Given to Neli Ulrich, PhD, MS, for Outstanding Research and Leadership
CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer
Insider Insights: Unveiling Takeaways from AACR 2024
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer